| Identification | Back Directory | [Name]
SLLK-NH2, Control Peptide for TSP1 Inhibitor | [CAS]
2918768-29-1 | [Synonyms]
SLLK-NH2, Control Peptide for TSP1 Inhibitor | [Molecular Formula]
C21H42N6O5 | [MOL File]
2918768-29-1.mol | [Molecular Weight]
458.6 |
| Chemical Properties | Back Directory | [Boiling point ]
837.382±65.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.144±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [pka]
12.039±0.10(predicted) | [Sequence]
Ser-Leu-Leu-Lys-NH2 |
| Hazard Information | Back Directory | [Uses]
SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine). | [in vivo]
TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides[1]. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice[2]. | [References]
[1] Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98. DOI:10.1161/ATVBAHA.114.304732
[2] Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178(6):2573-86. DOI:10.1016/j.ajpath.2011.02.039 |
|
| Company Name: |
TargetMol
|
| Tel: |
400-821-0310 15002144251 |
| Website: |
www.targetmol.cn/ |
|